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Abstract: Peripheral T-cell lymphomas (PTCL) are a heterogeneous, and often aggressive group of
non-Hodgkin lymphomas. Recent advances in the molecular and genetic characterization of PTCLs
have helped to delineate differences and similarities between the various subtypes, and the JAK/STAT
pathway has been found to play an important oncogenic role. Here, we aimed to characterize the
JAK/STAT pathway in PTCL subtypes and investigate whether the activation of the pathway correlates
with the frequency of STAT gene mutations. Patient samples from AITL (n = 30), ALCL (n = 21) and
PTCL-NOS (n = 12) cases were sequenced for STAT3, STAT5B, JAK1, JAK3, and RHOA mutations
using amplicon sequencing and stained immunohistochemically for pSTAT3, pMAPK, and pAKT. We
discovered STAT3 mutations in 13% of AITL, 13% of ALK+ ALCL, 38% of ALK− ALCL and 17% of
PTCL-NOS cases. However, no STAT5B mutations were found and JAK mutations were only present
in ALK- ALCL (15%). Concurrent mutations were found in all subgroups except ALK+ ALCL where
STAT3 mutations were always seen alone. High pY-STAT3 expression was observed especially in
AITL and ALCL samples. When studying JAK-STAT pathway mutations, pY-STAT3 expression was
highest in PTCLs harboring either JAK1 or STAT3 mutations and CD30+ phenotype representing
primarily ALK− ALCLs. Further investigation is needed to elucidate the molecular mechanisms of
JAK-STAT pathway activation in PTCL.
Keywords: lymphoma; T-cells; STAT3; RHOA; NGS
1. Introduction
Peripheral T-cell lymphomas (PTCLs) form a heterogeneous, uncommon, and often aggressive
group of non-Hodgkin’s lymphomas (NHL) representing approximately 10–15% of all new NHL
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diagnoses [1]. The most prevalent PTLCs are PTCL not otherwise specified (NOS), angioimmunoblastic
T-cell lymphoma (AITL), anaplastic lymphoma kinase–negative (ALK− ALCL), and anaplastic
lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL) [2,3].
Despite generally favorable response rates to chemotherapy, remissions are often not durable,
and as such the natural history of PTCL is characterized by relapses and refractory disease. For this
reason, upfront hematopoietic stem cell transplantation (HSCT) is often recommended in first remission
for patients who are fit and have chemo-sensitive disease [4]. For patients who are not suitable for
transplantation, chances of long-term disease control are very limited, with an average progression-free
survival (PFS) of 5.5 months [5]. In this setting, optimal therapeutic approaches remain undefined
representing an unmet clinical need.
Recent advances in the molecular and genetic characterization of PTCL have helped to delineate
differences and similarities between the various subtypes [6]. Several recurrent mutations have been
identified in small subsets of patients potentially enabling more accurate disease classification and
guide treatment decisions. In AITL, the three most commonly identified genetic lesions occur in the
Tet methylcytosine dioxygenase 2 gene (TET2), the Ras homolog gene family, member A (RHOA),
and the isocitrate dehydrogenase 2 gene (IDH2). Besides AITL, TET2 mutations can be seen with
a high frequency also in PTCL-NOS with a T follicular helper cell phenotype [7]. RHOA, a small
GTPase participating in T-cell activation and polarization, has recently been found to have a specific
G17V mutation in 68% of AITL cases [8], predominantly in the background of TET2 mutations.
The overwhelming majority of IDH2 mutations in PTCL affect the R172 residue [9]. However, STAT3
mutations are relatively uncommon (5%) in AITL [10].
In ALK+ ALCL, the ALK chimeras activate STAT3, thus maintaining the neoplastic phenotype in
ALK+ ALCL. In concordance with this, gene expression profiling has revealed a transcriptional gene
signature including ALK, TNFRSF8 (CD30), MUC1, Th17-associated genes (IL-17A, IL-17F, and ROR-γ),
a small group of immunoregulatory cytokines and receptors regulating STAT3 pathway [11].
A systematic characterization of the genetic alterations driving ALCL was recently undertaken
using sequencing strategies. Activating mutations of JAK1 and STAT3 genes were found in 20%
of ALK− ALCLs, 38% of which displayed double lesions [12]. As the JAK/STAT pathway has a
critical role in hematopoietic development, it is not surprising that it plays, when deregulated, an
important oncogenic role in lymphoproliferative malignancies [13]. Many cancers and hematologic
malignancies have been associated with the constitutive activation of the STAT family of proteins, which
depends on JAK-mediated tyrosine phosphorylation for transcriptional activation [14]. In particular,
activated JAK1/STAT3 and JAK2/STAT5 have been shown to facilitate T-cell transformation [15,16].
Activating mutations of JAK1-3 and STAT3-5 have also been found in a subset of NK/T-cell lymphomas,
non-hepatosplenic gamma-delta T-cell lymphoma, large granular lymphocytic leukemia and T-cell
prolymphocytic leukemia [10,17–22].
Here, we aimed to further characterize the JAK/STAT pathway in PTCL by investigating whether
the activation of the pathway quantified with immunohistochemistry correlates with the frequency
of JAK, STAT, and RHOA mutations. In addition, we associated JAK-STAT pathway activation with
prognosis and essential clinical and pathological parameters. Finally, we identified novel therapeutic
approaches for patients with high STAT3 phosphorylation using Reverse Phase Protein Array and
drug sensitivity data from the Broad Institute Cancer Cell Line Encyclopedia (CCLE).
2. Results
2.1. STAT3 Mutations Are Frequent in PTCLs
As STAT3 is constitutively expressed in both AITLs and ALCLs, we sequenced for STAT3 and
STAT5B mutations. The entire STAT3 gene and the hotspot SH2-domain of STAT5B were screened by
targeted amplicon sequencing in 63 patients with T-cell lymphoma. We discovered that 13% of AITL
and ALK+ ALCL cases harbored STAT3 mutations, while 17% of PTCL-NOS cases were found to harbor
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STAT3 mutations (Table 1). The highest frequency of STAT3 mutations was found in the ALK− ALCL
subgroup (38%). The frequency of STAT3 mutations in the entire patient cohort was 19%. While most
mutations were found in the SH2-domain of STAT3, we observed one K290T mutation in the coiled
coil domain and three patients harbored a P715L mutation in the transactivation domain (Figure 1
and Table S1). The most prevalent mutation type was the P715L mutation and the E616 deletion,
which were identified in three patients each. No STAT5B SH2-domain mutations were identified in this
cohort. JAK1 mutations were found in two ALK− ALCL patients (15%). Both mutations (G902R and
G1097C) were seen in the protein tyrosine kinase domain of JAK1. No JAK3 mutations were detected
in any subgroup.
Table 1. STAT3, JAK1/3, and RHOA mutation frequencies in PTCLs.
PTCL
Subtype n
STAT3 Mutation
Frequency
JAK1/3 Mutation
Frequency
RHOA Mutation
Frequency
Co-Occuring
Mutations
AITL 30 13% 0% 70% 10%
NOS 12 17% 0% 17% 8%
ALK+ ALCL 8 13% 0% 0% None
ALK− ALCL 13 38% 15% 0% 8%
All 63 19% 3% 37% 8%
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Figure 1. STAT3 structure and mutation sites in ALCL, AITL, and PTCL-NOS patients of the study 
cohort. 
As RHOA mutations are highly prevalent in AITL and have been found to cause activation of 
the MAPK/PI3K/AKT pathway and T cell receptor signaling, the hotspot mutation G17V was also 
screened [23,24]. The results showed that these mutations were frequent in AITL (70%) and PTCL-
NOS (17%) but remained absent in ALCLs (Table 1). Some cases harbored both STAT3 and RHOA 
mutations (10%). DNA samples from nodular lymphocyte predominant Hodgkin lymphoma with 
abundant follicular T helper cells (n = 13), were also available for STAT3/STAT5B and RHOA 
screening but no mutations were detected in these samples. 
2.2. STAT3 Phosphorylation Levels Are Highest in ALK+ and ALK− ALCL Cases 
To characterize JAK-STAT pathway activation, we stained for pY-STAT3, pMAPK, and pAKT 
in AITL (n = 29), ALCL (n = 20) and PTCL-NOS (n = 12) patients and control lymph nodes (n = 4) using 
immunohistochemistry (Supplementary Figure S1). The differences between disease groups were 
significant notably for phosphorylation of pY-STAT3 and recapitulated well previous reports [25]. 
Further post-hoc analysis showed that pY-STAT3 was shown to be more frequently phosphorylated 
in AITL (mean = 43.7%) and ALCL (ALK−: mean = 62.3%, ALK+: mean = 79.7%) patients compared to 
control lymph nodes (mean 12.6%; Figure 2). 
MAPK phosphorylation was significantly elevated in AITL patients (mean 10.5%) followed by 
ALK− ALCL (mean 6.8%) and PTCL NOS (5.2%) when compared to control lymph node (Figure 2). 
No significant difference in pAKT levels between PTCL patients and control lymph nodes was 
observed. 
Figure 1. STAT3 structure and mutation sites in ALCL, AITL, and PTCL-NOS patients of the study cohort.
As RHOA mutations are highly prevalent in AITL and have been found to cause activation of
the M PK/PI3K/AKT pathway and T cell receptor signaling, the hotspot mutation G17V w s als
scr ened [23,24]. The results showed that these mutations were frequent in AITL (70%) and PTCL-NOS
(17%) but remained absent in ALCLs (Table 1). Some c ses harbo d both STAT3 and RHOA mutations
(10%). DNA samples from nodular lymphocyte predominant Hodgkin lymphoma with abundant
follicular T helper cells (n = 13), were als av ilable for STAT3/STAT5B and RHOA screening but no
mutations were detected in these samples.
2.2. STAT3 Phosphorylation Levels Are Highest in ALK+ and ALK− ALCL Cases
To characterize JAK-STAT pathway activation, we stained for pY-STAT3, pMAPK, and pAKT
in AITL (n = 29), ALCL (n = 20) and PTCL-NOS (n = 12) pati nts and control lymph nodes (n = 4)
using immunohistochemistry (Supplementary Figure S1). The differences betwee isease groups
were significant notably for phosphorylation of pY-STA 3 and r capitulat d w ll previous reports [25].
Further post-hoc analysis showed th pY-STAT3 was shown to be more frequently ph sphoryla ed in
AITL (mean = 43.7%) and ALCL (ALK−: mean = 62.3%, ALK+: mean = 79.7%) patients compared to
control ly ph odes (me 12.6%; Figure 2).
MAPK osphorylation was significantly elevated in AITL patients (mean 10.5%) followed by
ALK− ALCL (mean 6.8%) and PTCL NOS (5.2%) when compared to control lymph node (Figure 2).
No significant difference in pAKT levels between PTCL patients nd contr l lymph nodes was observed.
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significant. 
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Figure 2. Phosphorylation percentage of pY-STAT3, MAPK, and AKT in PTCL subgroups and healthy
controls (n = 2–3) analyzed by im unohistochemistry. Individual dots represent the proportion of
positive cells for pSTAT3, pMAPK, and pAKT. Boxplots represent the median and interquartile range
of protein phosphorylation levels. The antibodies use were pecific for Tyr705 (pStat3), Thr202/Tyr204
(pMAPK), and Thr450 (pAKT). Comparison was analyzed with ANOVA and post-hoc tests between
disease groups and healthy controls. *: p < 0.05; **: p < 0.01, ****: p < 0.00 1; ns: not significant.
To confirm the findings and study STAT3 activation in other T cell malignancies, we measured
STAT3 and pY-STAT3 levels by We ern blotting in ALCL, acute T-lymphoblastic leukemia (T-ALL),
NK/T-cell lymphoma (NKT), T-cell large granular lymphocyte leukemia (T-LGL), and PTCL cell lines
(Figure 3). We confirmed high phosphorylation of pY-STAT3 (Tyr705) in ALCL but not in other T cell
malignancies. Total STAT3 was most promine t in PTCL, ALCL and T- LL cell li es. High JAK3
phosphorylation w s observed in SupM2, Karpas299 and TLRB1 (ALCL) as well as NKL (NKT) cell
lines and was n t associated with pY-STAT3 phosphorylation.
To further i vestigate the association of protein expression to transcriptome data, we compared the
JAK1, JAK3, AKT, and MAPK RNA level expression with STAT3 RNA level expression and pSTAT3Tyr705
phosphorylation defined with reverse phase protein arrays (RPPA) from the CCLE database (Figure S2).
Both STAT3 expression (535 vs. 198 CPM p = 0.003, t-test) and phosphorylation (3.6 vs. −0.10 RPPA unit,
p < 0.001) were observed to be superior in ALCL than non-ALCL malignant T c lls s shown in Figure 2.
Higher JAK3 expression was noted in ALCL o r n n-ALCL lines (364 vs. 53 CPM, p < 0.001), and
correlated with STAT3 expr ssion (r = 0.60, p = 0.01). Moreover, higher MAPK expression was detected
in ALCL over non-ALCL cell lines (127 vs. 68, p = 0.05), which correlated with STAT3 expression (r =
0.65, p = 0.006). No correlation between STAT3 and JAK1 or AKT expr sion was observed.
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Figure 3. Western blot of p-STAT3 (Tyr705), STAT3, p-JAK3 (Tyr980/981), and JAK3 was characterized
in T cell malignancy cell lines. Beta-ACTIN is used as a reference protein.
2.3. STAT3 Phosphorylation Is Associated with JAK1/STAT3 Mutation Status in CD30+ ALK− ALCLs
Next, we studied whether STAT3 mutations would be associated with STAT3, MAPK, and AKT
phosphorylation. No association between STAT3 mutation status and pY-STAT3, pMAPK, or pAKT (%)
expression was noted when studying all PTCL subtypes (Figure 4A). No association with pY-STAT3
phosphorylation was noted even after adjusting with tumor proportion (mean pSTAT3 77% vs. 66%
in STAT3 mutated vs. non-mutated PTCLs). Most of the mutations were noted in relatively low
variant allele frequencies (VAF 5–9%), which might in part explain the lack of correlation. Further
evidence for this observation was found from cell line data, as the four ALCL cell lines in Figure 2
exhibit high pY-STAT3 phosphorylation but only one of the cell lines harbored a JAK/STAT mutation
(Table S1). The TLBR1 cell line represents ALK− ALCL and harbors a known activating STAT3 missense
mutation S614R in the SH2 domain [26]. The other ALCL cell lines expressed ALK, which explains the
constitutive STAT3 activation. Both T-ALL cell lines MOLT4 and Jurkat also harbor missense STAT3/5B
mutations but conversely, the cell lines did not exhibit any pY-STAT3 phosphorylation. This could be
explained by the mutations being localized elsewhere than in the activating SH2-domain.
Some PTCL cases harbored both STAT3 and RHOA mutations (8%). Our results showed that the
MAPK phosphorylation degree was higher in patients with RHOA mutations than patients without
RHOA mutations (RHOA-positive mean = 12.4% vs. RHOA-negative mean 5.7%, p = 0.005, t-test;
Figure 4B). Yet, RHOA mutation was not observed to be associated with STAT3 or AKT phosphorylation.
Phosphorylated STAT3 has been shown to induce CD30 expression in PTCL [27]. In addition,
STAT3 mutations are more frequent in CD30+ than CD30− T-cell lymphomas [28]. Therefore, we
sought to investigate the interaction between mutations in the JAK-STAT pathway, CD30 phenotype
and pY-STAT3 phosphorylation. Positive CD30 tumor phenotype was associated with higher STAT3
and AKT phosphorylation, but not with pMAPK (Figure S3A). Interestingly, pSTAT3 expression was
highest in samples with CD30+ tumors and simultaneous mutation in STAT3 or JAK1 (Figure 4C). This
phenotype was represented primarily by the ALK− ALCL subtype (p < 0.001, chi2 test, Figure 4D),
and their pSTAT3 expression (mean 68.7%) to stand above the mean of ALK− (62.3%) but below ALK+
ALCL (79.7%). We observed that 50% (6/12) of CD30+ ALK− ALCLs harbored a mutation in JAK1
or STAT3. Higher JAK1/STAT3 VAF trended for higher pY-STAT3 phosphorylation but the result
remained non-significant possibly due to sample size (81.3% vs. 61.1% mean pSTAT3 expression in
tumors with high (n = 4) vs. low (n = 4) JAK1/STAT3 VAF p = 0.22, t-test). Unexpectedly, lowest STAT3
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phosphorylation was observed in CD30− patients with a STAT3 gene mutation. Interestingly, all three
in-frame E616 deletions were found in CD30− AITL cases.
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Figure 4. Comparison of the phosphorylation level of (A) STAT3, MAPK, and AKT by STAT3 mutation
status and by (B) RHOA mutation status (t-test). The phosphorylation level of pStat3 (Tyr705), pMAPK
(Thr202/Tyr204) and pAKT (Thr450) was measured by immunohistochemistry. (C) Combinatory effect
of CD30 phenotype and JAK1 or STAT3 mutation status on pSTAT3 expression was tudied with
one-way ANOVA and post-hoc correction. Green dots correspond to patients with STAT3 mutations,
the red dot correspond to a patient with JAK1 mutation and blue dots correspond to samples without
mutations in JAK1 or STAT3. (D) Frequency table of patients by CD30 phenotype and JAK1 or STAT3
mutation status (rows) and different PTCL histologies (columns). *: p < 0.05; ns: not significant.
EBV status has been shown to be associated with STAT3 activation in B cell lymphomas [29].
No associations between STAT3, MAPK, and AKT phosphorylation and EBV+ tumors could be
observed in our PTCL cohort (Figure S3B).
As fixation rate differs in samples of various origin and size, we investigated their association
with STAT3, MAPK, and AKT phosphorylation. The sample cohort included 9 biopsy samples and 52
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excised tumors. Biopsy samples were associated with higher pY-STAT3 but not with MAPK or AKT
phosphorylation (Figure S4A). Moreover, correlation between pY-STAT3 and sample size remained
non-significant (Figure S4B). Therefore, we hypothesize the difference to be due primarily to biological
rather than technical reasons. Except for four samples, the sample cohort consisted of lymph node
tissue samples. AKT phosphorylation was higher in lymph node samples, while no difference was
observed between pY-STAT3 and MAPK phosphorylation levels (Figure S4B).
To further elucidate the spatial localization of STAT3 phosphorylation, 6 T-cell lymphoma samples
(5 AITL, and 1 ALCL) and 2 NLPHL samples were stained for pY-STAT3, PD1, CD4, and CD8 using
multiplex immunohistochemistry. Of the 5 AITL samples, two harbored STAT3 mutations at 5% and
7% VAF, respectively. We found that the staining pattern or level of pY-STAT3 phosphorylation was
not associated with STAT3 mutation status (Figure 5).
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Figure 5. IHC stainings of four angioimmunoblastic T-cell lymphoma (AITL) lymph node samples.
(A). Samples containing low amount of pSTAT3. (B). Samples containing high amounts of pSTAT3.
Each slide has been digitalized with a 20× lens and similar exposure time per channel. Images have
been further magnified 30× for visualization purposes. The first four rows of images represent single
stainings of dapi counterstain, CD4, PD1, and pSTAT3 (Tyr705), respectively, and the last figure their
composite image. Staining: red = CD4, blue = PD1, green = pSTAT3.
2.4. High pY-STAT3 Expression Is Associated with CD3− CD5− CD7− CD30+ Immunophenotype Common
to ALCL
To understand the association of JAK-STAT signaling pathway activity with clinical determinants,
we combined pY-STAT3, pMAPK, and pAKT proportion defined by IHC with information on PTCL
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disease histology, stage, peripheral blood lactate dehydrogenase (LD) level at diagnosis, survival status,
STAT3 and RHOA mutation status (Figure 6). We noted that pY-STAT3, pMAPK, and pAKT expression
did not correlate with each other. High pY-STAT3 expression was noted to be associated with ALCL
histology as presented before (Figure 2). No association with survival status (p = 0.17, t-test), disease
stage (p = 0.40, one-way ANOVA), LD level (r = -0.13, p = 0.31, Pearson correlation), STAT3 (p = 0.56,
t-test) or RHOA mutation status (p = 0.11, t-test) was noted.
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To correlate the expression of the JAK-STAT signaling pathway with immunohistochemical
and serological factors of disease pathology, we investigated EBV seropositivity, and expression
of immunophenotype markers as defined with IHC (Figure 6). Lower pY-STAT3 expression was
associated with negative CD3 (37.7% and 75.4% mean pSTAT3 expression, p < 0.001, t-test), CD5 (42.8%
and 68.4%, p = 0.03, t-test), CD7 (45.2% and 64.6%, p = 0.01) and positive CD30 phenotype (Figure
S4A) designating ALCL immunophenotype as reported in Figure 2 [30]. No association with EBV
seropositivity (Figure S4B), CD4 (p = 0.86, t-test) or CD8 (p = 0.35, t-test) immunophenotype nor MIB
proliferation index (r = 0.20, p = 0.19, Pearson correlation) was noted.
2.5. Novel Potential Inhibitors of STAT3 Activation
In myeloproliferative neoplasms the JAK-STAT signaling pathway can be inhibited with the
JAK1/JAK2 inhibitor ruxolitinib and in rheumatoid arthritis with less selective JAK inhibitors such
as tofacitinib and baricitinib [31]. Several other pharmacological compounds affecting the JAK-STAT
pathway are currently investigated in clinical trials [31]. We hypothesized that drugs investigated for
other indications might induce differential sensitivity in cancer cell lines with active JAK-STAT signaling.
By comparing cytotoxicity measured by the area under the curve (AUC) of 265 investigational and
accepted compounds in pSTAT3 high (n = 27) and low (n = 583) cancer cell lines reported in the Sanger
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GDSC and CCLE databases respectively, we identified the JAK-STAT inhibitor ruxolitinib to be more
potent in pSTAT3 high cell lines (Figure 7). Interestingly, we discovered also the cell cycle checkpoint
kinase Chk1/2 inhibitor AZD7762, the poly ADP ribose polymerase (PARP) inhibitor talazoparib and
the nucleoside analog gemcitabine to exhibit most sensitivity in pSTAT3 cell lines.
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Figure 7. Differential drug sensitivity in pSTAT3 high (n = 27) and low (n = 583) cancer cell lines. The
pSTAT3 phosphorylation level has been quantified with reverse phase protein array (RPPA, cut-off
pSTAT3Tyr705 = 1). The drug sensitivity data represent the area under the curve (AUC) response of
265 different phamacological compounds, and has been retrieved from the Sanger GDSC dataset. The
RPPA data are derived from the Broad Institute the Cancer Cell Line Encyclopedia (CCLE) database.
Differential drug sensitivity has been computed with multiple T-tests, and the fold change defined
as the m an AUC ratio in pSTAT3 high-to-low cell lines. Drugs with a fold change (FC) less than 1.0
are more sensitive in pSTAT3 high cell lines. The target pathway of the top pharmacological hits have
been color-labeled.
3. Discussion
PTCL patients face unfavorable prognosis as chemotherapy results in poor 5-year overall survival
rates [32]. Targeted treatment options only exist for ALK+ ALCL, but are urgently needed for other
PTCL entities. Using targeted sequencing, we demonstrated that STAT3 alterations are prevalent in all
PTCL subgroups. We discovered that 13% of AITL and ALK+ ALCL cases and 17% of PTCL-NOS cases
harbored STAT3 mutations. The highest prevalence of STAT3 mutations was seen in ALK− ALCL (38%).
The mutations were found mostly in the SH2-domain of STAT3 but also in the coiled coil (K290T) and
transactivation domains (P715L). While we observed no association between overall STAT3 mutation
and pY-STAT3 phosphorylation, pY-STAT3 phosphorylation was most elevated in PTCL patients with
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combined CD30+ tumor phenotype and mutations in either STAT3 or JAK1 representing primarily
ALK− ALCLs and suggesting heterogenous mechanisms of STAT3 activation. Unexpectedly, PTCLs
with CD30- phenotype and STAT3 mutation were associated with lowest pY-STAT3 phosphorylation.
As CD30 transcription is regulated by pSTAT3, the result might be explained by non-activating
mutations or interference in the JAK-STAT pathway [27].
JAK/STAT mutations have been previously reported in PTCL-NOS, ALCL, and AITL [12,33,34],
supporting the results of our study. The frequency of JAK/STAT mutations in different cohorts of PTCL
has been reported to be around 20% which compares well to the mutation frequency seen in this study.
In the whole cohort one of the most prevalent STAT3 mutation was an in-frame deletion of E616, which
was identified in three AITL patients. The E616 deletion has been shown to induce myeloid malignancy
in a mouse bone marrow transplantation model [19]. The mutation has been observed previously in
AITL, but also in adult T-cell lymphoma [10,35]. The STAT3 mutation P715L observed in two ALK−
ALCLs and one PTCL-NOS case has been observed in NKTL previously [36].
Some AITL and PTCL-NOS cases harbored concurrent STAT3 and RHOA mutations (3/30 AITL
and 1/12 PTCL-NOS). The incidence of RHOA mutations in our AITL cohort was 70%, which is
somewhat higher than the incidence seen in previous AITL cohorts (68% and 53%) [8,23]. In PTCL-NOS
the mutation incidence was 17% (2/12). Our results also showed that the MAPK phosphorylation
degree correlated with RHOA mutations in our PTCL cohort.
Although this study included limited number of patients representing various PTCLs subtypes, our
results suggest that pY-STAT3 is frequently constitutively phosphorylated in PTCL, especially in ALCLs
and AITLs, but this was associated with STAT3 mutations in only a fraction of PTCL samples. Previous
studies have reported mechanisms underlying the constitutive activation of STAT3 independent of
STAT3 mutations. Gain-of–function mutations involving JAK genes have been implicated in activating
STAT3 and contributing to the pathogenesis of hematologic malignancies and solid tumors [37,38].
Various cytokines (e.g., IL-6, IL-10, and IL-11) that are released into the microenvironment by tumor
cells have also been shown to activate STAT3 [39]. Another mechanism of STAT3 activation is possible
through the deregulation of suppressors of the JAK/STAT pathway such as SOCS3 [40] leading to
constitutive STAT activation and oncogenesis. In addition, further studies are needed to combine any
association with JAK-STAT pathway activation and expression of essential transcription factors such
as GATA3 and Tbet, which define new subclasses of PTCL-NOS with prognostic consequences, where
GATA3 signatures are associated with worse prognosis [41,42].
In our cohort high pSTAT3 expression correlated with the CD3− CD5− CD7− CD30+
immunophenotype typical for ALCL. No association with neither immunophenotype markers nor
essential clinical variables such as survival status, disease stage, MIB proliferation index or LD level
was seen.
By comparing cytotoxicity measured by the area under the curve (AUC) of 265 investigational and
accepted compounds in pSTAT3 high and low cancer cell lines, we identified novel potential inhibitors
of STAT3 activation. The JAK-inhibitor ruxolitinib was among the top candidates. Ruxolitinib, a
selective JAK1/2 inhibitor approved by the FDA for myeloproliferative neoplasms, is being studied in
relapsed B-cell lymphoma and PTCL (NCT01431209).
Among compounds exhibiting most sensitivity in pSTAT3 high cell lines were the cell cycle
checkpoint kinase Chk1/2 inhibitor AZD7762, the poly ADP ribose polymerase (PARP) inhibitor
talazoparib, and the nucleoside analog gemcitabine. In phase II studies, gemcitabine monotherapy has
shown activity against T-cell lymphomas. Zinzani et al. reported a 70% response rate in a phase II study
of 44 pretreated patients with mycosis fungoides or cutaneous PTCL-unspecified [43]. In another phase
II study, gemcitabine was given in combination with romidepsin to relapsed/refractory PTCL patients
but the synergy observed in preclinical phase did not improve clinical outcomes [44]. Moreover,
gemcitabine has been tested in combination with cisplatin and methylprednisolone as both upfront
treatment and in relapsed/refractory PTCL, but did not significantly improve OS [45,46].
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4. Materials and Methods
4.1. Patients and Cell Lines
Samples from 63 patients with PTCL were collected. Of these samples 30 were AITL, 12 PTCL-NOS
and 21 ALCL (13 ALK− and 8 ALK+). Four control samples from normal lymph nodes were also
collected. The study was undertaken in compliance with the principles of the Helsinki Declaration and
was approved by the ethics committee in the Helsinki University Hospital (Finland). As the samples
studied were older diagnostic samples, the ethics committee required no written informed consent
(TEO 5326/04/046/06, Valvira 9115/05.01.00.06/2011, HUS 302/E0/2006, HUS/1230/2017). The clinical and
pathological characteristics of our study objects are summarized in Table S2.
4.2. Cell Lines and Cell Culture Conditions
The T-cell lines were cultured in RMPI-1640 medium including L-glutamine (Gibco, Grand Island,
NY, USA) supplemented with 10% (L82, Karpas299, TLRB1, Molt4, Jurkat, and NKL cell line) or 20%
(SupM2, MTA, MOTN1, and SMZ1 cell line) fetal bovine serum (FBS, Gibco) and Penicillin/Streptomycin
(100 U/l, Gibco). IL2 (10ng/mL, MedChemExpress, Monmouth Junction, NJ, USA) was added for
culturing of TLRB1 and NKL cells. Suspension cells were maintained at a density of 2.0–8.0 × 105.
Culturing was done in an incubator at 37 ◦C and 5% CO2 with 90% humidity.
4.3. Sample Preparation
According to standard clinical procedure, fresh tissue samples consisting mostly of lymph nodes
(LN) were fixated in formalin and embedded in paraffin (FFPE) in the central pathology laboratory of
Helsinki University Hospital (HUCH), Finland. Consequently, we cut 3.5 µm whole-tissue sections on
Superfrost objective slides (Kindler O Gmbh, Freiburg, Germany).
4.4. DNA Extraction
DNA was extracted from FFPE tissue blocks. Ten 10µm sections were cut with standard microtome
(Leica SM2000 R Sliding Microtome, Wetzlar, Germany) using disposable blades. Excess paraffin was
trimmed off and the sections were collected into sterile 1.5 mL microcentrifuge tubes. The sections
were then deparaffinized with three pre-warmed (55 C) xylene washes followed by 95%, 75%, and 50%
ethanol rinses. The tissue pellets were dried briefly at 37 ◦C to remove traces of ethanol. The pellets
were then digested with 20 µL proteinase K (20 mg/mL proteinase K, Roche Diagnostics GmbH,
(Mannheim, Germany) and 180 µL digestion buffer (10 mM Tris-HCl, pH 8.0 100 mM EDTA, pH
8.0 50 mM NaCl, and 0.5% SDS). Samples were incubated at 55 ◦C with mild agitation for 3 to 72 h.
Fresh Proteinase K was added every 24 h followed by heat inactivation at 90 ◦C for 1 h after the
tissue had been fully dissolved. For phenol-chloroform extraction, equal volume of phenol (Amresco,
Solon, OH, USA) was added and vortexed. After spinning for 3 min at 14,000 rpm, the aqueous
layer was transferred to a new tube. Then, an equal volume of phenol-chloroform-isoamyl alcohol
(25:25:1) (Invitrogen, Carlsbad, CA, USA) was added, and the solution was vortexed and spun for
5 min at 14,000 rpm in a microcentrifuge. The aqueous layer was again transferred to a new tube
and treated with RNase A at 100 µg/mL for 1 h at 37 ◦C. To remove any remaining RNase A phenol
and phenol-chloroform-isoamyl alcohol steps were repeated. The aqueous layer was transferred to
a new tube and the DNA was precipitated with 1/10 volume of 3 M sodium acetate and 1 volume
of isopropanol. After thorough mixing, the solution was placed in a freezer for 30 min then spun at
14,000 rpm at 4 ◦C in a microcentrifuge for 10 min. The supernatant was discarded, and the pellet was
washed with 1 mL 70% cold ethanol and spun at 14,000 rpm for 10 min at 4 ◦C. The supernatant was
carefully discarded, and the pellet dried and finally suspended with 50 µL dH2O.
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4.5. Targeted Deep Amplicon Sequencing
Locus-specific primers were designed for STAT3, STAT5B, JAK1, JAK3, and RHOA mutation
hotspots using Primer3 with user-defined parameters (http://primer3.wi.mit.edu/). After designing
the locus-specific primer sequences (Table S3), sequence tails corresponding to the Illumina adapter
sequences, were added to the 5′ end of the forward and reverse locus-specific primers, respectively.
All oligonucleotides were ordered from Sigma-Aldrich (St. Louis, MO, USA). Deep targeted amplicon
sequencing of known recurrent somatic mutations in the genes STAT3, STAT5B, JAK1, JAK3, and RHOA
was performed with the Illumina MiSeq platform (San Diego, CA, USA)as previously described [47].
The data were analyzed with a bioinformatics pipeline, which is based on calling of variants with
certain count/frequency of reads and filtering out false positives using the estimated error rate and
quality data of amplicon reads.
4.6. Immunohistochemistry
4.6.1. Single Color Immunohistochemistry
Tissue sections were deparaffinized, rehydrated in graded ethanol series and then subjected
to heat-induced epitope retrieval in Tris-HCl (10 mM Tris, pH 8.5, 25 min; for Phospho-MAPK
and Phospho-AKT) or in EDTA buffer (10 mM EDTA, pH 8.0, 20 min; for Phospho-Stat3 and
-5) in a Pre-Treatment module (DAKO/Agilent Technologies, Waltham, MA, USA). Samples were
stained using LabVision autostainer (Thermo Fisher Scientific, Fremont, CA, USA). The endogenous
peroxidase activity was blocked with Peroxidase-Blocking Solution (Dako/Agilent Tehnologies).
The samples were treated with primary antibody for 1 h at RT. The antibodies used were rabbit
monoclonal antibodies from Cell Signaling (Leiden, the Netherlands): clone Tyr705 for pY-STAT3
(1:300), clone Thr202/Tyr204 for Phospho-p44/42MAPK (1:300) and Thr450 for Phospho-AKT (1:100).
BrightVision polymerisation technology was utilized to prepare polymeric HRP-linker antibody
conjugates (ImmunoLogic, Duiven, the Netherlands) and 3,3-diaminobenzidine (DAB) was used as
chromogen. Sections were counterstained with Mayer’s hematoxylin (Dako/Agilent Tehnologies) and
mounted with Eukitt (Honeywell Fluka, Frankfurt, Germany).
Protein expression was defined by visual examination. Five representative 400×-magnified
high-power field-of-view (FOV) were selected, and protein expression (%) was estimated as the
proportion of positive cells of 100 cells analyzed by FOV. Finally, the mean proportion of positive cells
was calculated and used for statistical analyses.
4.6.2. Multiplex Immunohistochemistry
All phases were performed in room temperature (if not otherwise specified) and protein blocking
as well as antibody incubations were performed in a humid chamber. The slides were washed with
0.1% Tween-20 (Thermo Fisher Scientific) diluted in 10 mM Tris-HCL buffered saline pH 7.4 (TBS)
three times after peroxide block, each antibody staining, and fluorochrome reaction. Antibodies were
tested with normal lymph node and pY-STAT3 was validated with tissue samples from a patient with
large granular lymphocyte leukemia (Figure S5).
The slides were deparaffinized in xylene and rehydrated with graded series of ethanol and H2O.
HIER was performed in 10 mM Tris-HCl - 1 mM EDTA buffer (pH 9) in +99 ◦C for 20 min (PT Module,
Thermo Fisher Scientific). The peroxide activity was then blocked in 0.9% H2O2 solution for 15 min,
and 10% normal goat serum was subsequently applied (TBS-NGS) for 15 min. We applied the primary
antibody anti-PD1 (1:5000; clone PDCD1; LsBio, Seattle, WA, USA) diluted in TBS-NGS for 1 h 45 min,
and then anti-mouse horseradish peroxidase (HRP) conjugated secondary antibodies (Immunologic)
diluted 1:2 in washing buffer for 45 min. Then, we applied tyramide signal amplification (TSA) Alexa
Fluor 488 (PerkinElmer, Boston, MA, USA) diluted 1:50 in TBS on the slides for 10 min. In order to
multiplex antibodies, we denatured the primary antibody and quenched the enzymatic activity of HRP
by repeating HIER as well as performing peroxide and protein block similarly as above. We applied
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the primary antibody against pY-STAT3 (Tyr705; 1:2500; clone D3A7; CellSignaling) overnight in +4 ◦C,
anti-mouse HRP-conjugated secondary antibody diluted 1:5 in washing buffer for 45 min, and TSA
Alexa Fluor 555 (PerkinElmer) for 10 min. We repeated HIER, peroxide block and protein block as
above. Next, we applied anti-CD4 (1:150; clone EPR6855; Abcam, Cambridge, UK) diluted in TBS-NGS
for 3 h and later AlexaFluor647-conjugated secondary antibody (1:300; Thermo Fisher Scientific) and
Hoechst 33,342 (1 µg/mL; Sigma-Aldrich) counterstain diluted in washing buffer for 45 min. Finally,
we applied ProLong Gold (Thermo Fisher Scientific) to mount the slides.
The tissue slides were scanned with 20x magnification with the Panoramic P250 Flash II whole
slide scanner (3DHistech, Budapest, Hungary). We used DAPI, FITC, Cy3, and Cy5 filters and
visually-optimized exposure times.
4.7. Western Blot
Immunoblots were performed on whole-cell protein lysates according to standard techniques. All
primary antibodies (pJAK3Tyr980/981, clone D44E3; JAK3, clone D7B12; pY-STAT3Tyr705, clone D3A7;
STAT3, clone 124H6; beta-ACTIN, clone 13E5) were ordered from Cell Signaling Technology and
used at 1:1000 dilutions. Anti-mouse and anti-rabbit, both from Dianova, were used as secondary
HRP-coupled antibodies in a 1:5000 dilution. Development of the immunoblots was performed by
using Western Bright ECL (Advansta, Menlo Park, CA, USA). The original blots and densitometry
readings of each band is available in the Supplementary Materials (Figure S6 and Table S4).
4.8. CCLE and DepMap Data
All CCLE pre-processed data were downloaded from the CCLE data portal (https://portals.
broadinstitute.org/ccle/data). RPPA data dated 3 October2018, RNA-seq gene count data dated 29
September 2018, cell line annotation dated 26 December 2018, and mutation data dated 18 July 2018
were used. Gene counts were converted to CPM values using the edgeR and the TMM normalization
method without log transformation. The cut-off for high vs. low STAT3 phosphorylation was set to
pSTAT3Tyr705 = 1 (RPPA unit) based on the shape of the pSTAT3Tyr705 frequency histogram.
Area under the curve (AUC) drug sensitivity data annotated as “Sanger GDSC v17.3” and dated
March 2018 were downloaded from the Cancer Dependency Map portal (https://depmap.org/portal/
download/). Drugs not characterized in both pSTAT3 high and low cell line groups were removed
from the analysis. Cell lines with no pSTAT3 RPPA data were removed from the analysis.
4.9. Statistical Analysis
Comparison of continuous variables between two groups was computed with unpaired t-test and
between multiple groups with one-way ANOVA and post-hoc correction between disease groups and
healthy controls.
Overall survival was defined as the time from diagnosis to death or last follow-up. Patients alive at
the last follow-up date were censored. The log-rank test was used to compute Cox proportional-hazards.
Differential drug sensitivity was computed using t-test between pSTAT3 high (n = 27) and low
(n = 583) cancer cell lines. The fold change in drug sensitivity was defined as the mean AUC ratio
in pSTAT3 high-to-low cell lines. Drugs with a fold change (FC) less than 1.0 are more sensitive in
pSTAT3 high cell lines.
R 3.5.1. [48] and Prism 6.0 was used for statistical analyses. R packages edgeR 3.24.0, forestplot
1.7.2, survminer 0.4.3, ggplot2 3.2.1, and ComplexHeatmap 2.3.2 were used.
5. Conclusions
In summary, this study discovered that pY-STAT3 phosphorylation was associated with both ALK+
ALCLs and JAK1/STAT3 mutated CD30+ ALK− ALCLs suggesting a subgroup potentially benefitting
of JAK/STAT targeted therapy.
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